Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Charter Communications Inc
NASDAQ:CHTR
|
US |
Clinuvel Pharmaceuticals Ltd
Stock-Based Compensation
Clinuvel Pharmaceuticals Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Stock-Based Compensation
AU$2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Stock-Based Compensation
$16.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Stock-Based Compensation
$152m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Stock-Based Compensation
AU$1.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Stock-Based Compensation
AU$19.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Stock-Based Compensation
AU$940.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Stock-Based Compensation?
Stock-Based Compensation
2m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Stock-Based Compensation amounts to 2m AUD.
What is Clinuvel Pharmaceuticals Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-7%
Over the last year, the Stock-Based Compensation growth was 38%. The average annual Stock-Based Compensation growth rates for Clinuvel Pharmaceuticals Ltd have been -33% over the past three years , -7% over the past five years .
